#United States #South San Francisco #Centivax #Universal Immunity #Centi-Flu 01

Centivax Secures $37 Million in Financing for Universal Flu Vaccine and Expanding Therapeutics

Centivax, Inc., a pioneering clinical-stage biotechnology company focused on creating vaccines and therapies for universal protection, has recently announced that it successfully closed a substantial financing round totaling $37 million. This financing was led by Structure Fund, along with participation from several notable investors including Meiji Seika Pharma Co., Ltd., Sigmas Group, Kendall Capital Partners, and tech entrepreneurs Patrick and John Collison. The funding significantly boosts Centivax's efforts to advance its groundbreaking universal flu vaccine, Centi-Flu 01, as well as other projects in its extensive pipeline.

Establishing a Strong Foundation

This latest round of financing follows a previous $45 million oversubscribed Series A round completed in June 2025, which was crucial for initiating Phase 1 clinical studies. According to Dr. Jacob Glanville, founder and CEO of Centivax, the funds secured earlier enabled the company to enroll nearly all 180 participants for the Phase 1a clinical trials. With this new capital influx, Centivax is poised to seamlessly proceed into Phase 2 trials, a critical phase in the development of its universal flu vaccine program.

Centi-Flu 01: A Game-Changer in Flu Vaccination

Traditional seasonal flu vaccines typically require reformulation twice annually due to the constantly evolving nature of influenza strains. This process often leads to variable vaccine effectiveness, ranging from 10% to 60%, and they remain entirely ineffective against pandemic strains. In contrast, Centi-Flu 01 targets conserved regions of the influenza virus that are resistant to mutation, thereby providing broad and reliable immunity. This innovative approach seeks to eliminate the need for annual modifications, setting Centivax apart from conventional vaccine strategies.

The current Phase 1 study—encompassing more than 300 participants—is designed not only to assess safety but also to evaluate efficacy against a comprehensive panel of 24 influenza virus strains. The results of this assessment are anticipated in 2026. Phase 2 trials are on track to commence in early 2027, enrolling 500 subjects to robustly evaluate the vaccine's protective capabilities compared to currently available flu vaccines.

Expansion of Portfolio and Manufacturing Innovations

In addition to advancing Centi-Flu 01, the recent financing allows Centivax to expedite the development of four follow-on clinical candidates, which are poised to enter manufacturing and clinical readiness stages. Among these initiatives are programs focused on cancer therapy, a malaria vaccine, a universal antivenom, and an Alzheimer’s preventative—highlighting the versatility and potential of Centivax's immune-engineering platform.

Furthermore, the financing supports the implementation of Centivax's innovative scalable, cell-free manufacturing process by 2026. This facility aims to significantly reduce production costs and timelines while enhancing technical reliability across the board, facilitating a quicker route to global access for Centi-Flu and subsequent program rollouts.

A Bright Future for Universal Immunity

The ability of Centivax to attract significant investment despite a challenging funding landscape attests to the strength of its programs and the leadership underpinning the company. As highlighted by Stephanie Wisner, Co-Founder and Chief Business Officer of Centivax, this rapid progression into Phase 2 will not only fuel business development but also mitigate logistical constraints commonly associated with aligning clinical studies to flu seasons.

In summary, the new funding empowers Centivax to enhance its universal immunity solutions, with Centi-Flu 01 leading the charge toward greater public health resilience amidst seasonal and pandemic influenza threats. Centivax remains committed to validating its platform's potential across a myriad of disease areas, paving the way for transformative advancements in infectious disease prevention and treatment.

For further information, Centivax operates out of South San Francisco, California, and looks forward to expanding its reach within the global healthcare landscape. To stay updated, visit Centivax's official website or follow them on social media.